Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion

Health-Related Quality of Life, Treatment Satisfaction, and Costs Associated With Intraperitoneal Versus Subcutaneous Insulin Administration in Type 1 Diabetes: A randomized controlled trial

(2010) S. J. Logtenberg et al.   DIABETES CARE

The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis

(2010) Sebastio Perrini et al.   JOURNAL OF ENDOCRINOLOGY

Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes: A randomized controlled trial

(2009) S. J. Logtenberg et al.   DIABETES CARE

Biological effects of growth hormone on carbohydrate and lipid metabolism

(2009) Archana Vijayakumar et al.   GROWTH HORMONE & IGF RESEARCH

The Role of IGF-system in Vascular Insulin Resistance

(2008) H. Arnqvist   HORMONE AND METABOLIC RESEARCH

Comparison of Pancreas-Transplanted Type 1 Diabetic Patients with Portal-VenousVersusSystemic-Venous Graft Drainage: Impact on Glucose Regulatory Hormones and the Growth Hormone/Insulin–Like Growth Factor-I Axis

(2008) Jan Frystyk et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality

(2008) M. P. Brugts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM